ARTICLE | Product Development
O’Day’s expansive task at Gilead
How incoming Gilead CEO O’Day could make the biotech’s move into new therapeutic areas a success
December 15, 2018 4:43 AM UTC
A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of virology.
The first read of his success may not come until 2021, after Gilead launches its first autoimmune drug. ...